A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC

7067 Background: ZD6474 is a once-daily oral therapy that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptor (VEGFR)-dependent tumor angi...